Telisotuzumab Vedotin Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Telisotuzumab vedotin (Teliso-V) is an antibody drug conjugate that targets the MET receptor.

Clinical Use

In the first in-human phase I trial for Teliso-V, NSCLC patients with MET-overexpressing tumors received monotherapy. The results of this innovative trial indicated favorable safety and tolerability responses and also showed promising antitumor activity in NSCLC patients with MET overexpression.

Telisotuzumab Vedotin Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Telisotuzumab Vedotin Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
TargetMol Chemicals Inc.		support@targetmol.com	United States	38832	58
Shanghai YuanYe Biotechnology Co., Ltd.	021-61312847; 18021002903	3008007409@qq.com	China	71826	60
Wuhan Chemstan Biotechnology Co., Ltd.	027-65317797 15926423062	422450190@qq.com	China	10308	58
Wuhan Peptide Core Biotechnology Co., Ltd	027-65317797 13667154760	1096814016@qq.com	China	10711	58
bioleaper	4000880777 17585207275	guojing@bioleaper.com	China	5616	58
TargetMol Chemicals Inc.	15002134094	marketing@targetmol.cn	China	26014	58
Atagenix Laboratories	027-87008169 17762441161	info@atagenix.com	China	9914	58
Selleck Chemicals	400-668-6834	info@selleck.cn	China	6071	58

---

• Telisotuzumab Vedotin
• Telisotuzumab vedotin (ADC)
• Telisotuzumab vedotin (anti-c-Met)
• 1714088-51-3